Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab.
Journal Information
Full Title: Ann Neurol
Abbreviation: Ann Neurol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Potential Conflicts of Interest C.R. is an employee and shareholder of F. Hoffmann‐La Roche. A.V.‐D. reported grants from F. Hoffmann‐La Roche during the conduct of the study."
Funding Disclosure
Evidence found in paper:
"This work was supported by F. Hoffmann‐La Roche, which developed and markets OCR."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025